BioGenerator and the state-funded Missouri Technology Corp. have invested in a cancer-drug startup that’s based on Washington University research.
The startup, Accuronix Therapeutics, raised a total of $625,000, with BioGenerator as the lead investor. Accuronix is developing drugs for difficult-to-treat forms of cancer, starting with pancreatic cancer.